AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39479329 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 111
Study 39479373 — intervention group
Group type: EXPERIMENTAL
Intervention: Amaze™ asthma disease management platform
Number of subjects: 159
Study 39479758 — intervention group
Group type: EXPERIMENTAL
Intervention: AWARE intervention
Number of subjects: 103
Study 39479758 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 103
Study 39479862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 334
Study 39479862 — intervention group
Group type: COMPARATOR
Intervention: Conventional second-line chemotherapy
Number of subjects: 334
Study 39480040 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly l-lactic acid (PLLA-SCA)
Number of subjects: 21
Study 39480040 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxylapatite (CaHA-R)
Number of subjects: 21
Study 39480129 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01%
Number of subjects: 187
Study 39480129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 39480221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous access
Number of subjects: 1479
Study 39480221 — intervention group
Group type: COMPARATOR
Intervention: Intravenous access
Number of subjects: 1479
Study 39480285 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)
Number of subjects: 0
Study 39480285 — intervention group
Group type: COMPARATOR
Intervention: Services as usual (SAU)
Number of subjects: 0
Study 39480364 — intervention group
Group type: EXPERIMENTAL
Intervention: Eigen radiomic features
Number of subjects: 1750
Study 39480364 — intervention group
Group type: COMPARATOR
Intervention: Clinical model incorporating cardiovascular risk score, Agatston score, and presence of obstructive coronary artery disease
Number of subjects: 1750
Study 39480364 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including eigen radiomic features
Number of subjects: 1750
Study 39480379 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 1720
Study 39480379 — intervention group
Group type: COMPARATOR
Intervention: Control second-generation drug-eluting stent (DES)
Number of subjects: 1720
Study 39480379 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-SES
Number of subjects: 1720
Study 39480379 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography substudy
Number of subjects: 1720
Study 39480379 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography substudy
Number of subjects: 1720
Study 39480380 — intervention group
Group type: EXPERIMENTAL
Intervention: TTVR with the EVOQUE tricuspid valve replacement system plus optimal medical therapy (OMT)
Number of subjects: 392
Study 39480380 — intervention group
Group type: COMPARATOR
Intervention: OMT alone
Number of subjects: 392
Study 39480391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon or Radiofrequency Ablation
Number of subjects: 346
Study 39480422 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician peer comparison
Number of subjects: 509269
Study 39480422 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient informational mail
Number of subjects: 509269
Study 39480422 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinician peer comparison and patient informational mail
Number of subjects: 509269
Study 39480422 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 509269
Study 39480422 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 509269
Study 39480424 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-magnitude mechanical signals (LMMS) (0.3 g at 32-37 Hz) for 10 minutes daily for 6 months
Number of subjects: 40
Study 39480424 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) signals for 10 minutes daily for 6 months
Number of subjects: 40
Study 39480453 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (40 mg orally, twice daily, days 1-7) combined with temozolomide (150-200 mg/m2 orally, days 1-5) for 6 cycles
Number of subjects: 447
Study 39480453 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with temozolomide (150-200 mg/m2 orally, days 1-5) for 6 cycles
Number of subjects: 447
Study 39480493 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS® report cards (Arm 1)
Number of subjects: 110
Study 39480493 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Arm 2)
Number of subjects: 110
Study 39480530 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI every 2 weeks with routine G-CSF prophylaxis
Number of subjects: 92
Study 39480645 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 511
Study 39480645 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 511
Study 39480645 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proADM
Number of subjects: 511
Study 39480670 — intervention group
Group type: EXPERIMENTAL
Intervention: Various methods for assessing volume overload and congestion including plasma biomarkers, measurement of blood volume from [131I]-human serum albumin, sonographic modalities, implantable devices, invasive measurements (right heart catheterization), and impedance methods.
Number of subjects: 0
Study 39480764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprubart (anti CD40L antibody) administered intravenously, 6 infusions every 2 weeks at doses of 1 mg/kg, 2 mg/kg, 4 mg/kg, and 8 mg/kg
Number of subjects: 54
Study 39480784 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiobook mobile application (poetry) for 4 weeks
Number of subjects: 60
Study 39480784 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention evaluation
Number of subjects: 60
Study 39480784 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention evaluation
Number of subjects: 60
Study 39480792 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation combined with lumbo-pelvic stability core training
Number of subjects: 40
Study 39480792 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 40
Study 39480821 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital self-efficacy training combined with ecological momentary assessment (EMA)
Number of subjects: 93
Study 39480821 — intervention group
Group type: COMPARATOR
Intervention: EMA only (control group)
Number of subjects: 93
Study 39480821 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital self-efficacy training
Number of subjects: 93
Study 39480988 — intervention group
Group type: COMPARATOR
Intervention: Glucagon-Like Peptide-1 Receptor Agonists
Number of subjects: 0
Study 39481054 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin (EV) 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle
Number of subjects: 46
Study 39481070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (cryptogenic stroke patients)
Number of subjects: 878
Study 39481328 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula at 30 L/min (HFNC-30)
Number of subjects: 137
Study 39481328 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula at 50 L/min (HFNC-50)
Number of subjects: 137
Study 39481328 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 137
Study 39481395 — intervention group
Group type: EXPERIMENTAL
Intervention: Camizestrant 75 mg
Number of subjects: 240
Study 39481395 — intervention group
Group type: EXPERIMENTAL
Intervention: Camizestrant 150 mg
Number of subjects: 240
Study 39481395 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant 500 mg
Number of subjects: 240
Study 39481425 — intervention group
Group type: EXPERIMENTAL
Intervention: DynamX bioadaptor (Elixir Medical)
Number of subjects: 2399
Study 39481425 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting DES (Resolute Onyx and Onyx Trustar, Medtronic)
Number of subjects: 2399
Study 39481541 — intervention group
Group type: EXPERIMENTAL
Intervention: Mungbean dal with fresh guava (3.2 mg iron; ∼170 mg vitamin C; molar ratio ∼18:1)
Number of subjects: 200
Study 39481541 — intervention group
Group type: COMPARATOR
Intervention: Mungbean dal only (3.0 mg iron; vitamin C:iron molar ratio ∼0.5:1)
Number of subjects: 200
Study 39481576 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided shear wave elastography (EUS-SWE)
Number of subjects: 62
Study 39481576 — intervention group
Group type: COMPARATOR
Intervention: Fibrosis-4 Index (FIB-4)
Number of subjects: 62
Study 39481576 — intervention group
Group type: COMPARATOR
Intervention: Vibration-controlled transient elastography (VCTE)
Number of subjects: 62
Study 39481880 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant platinum-based chemotherapy followed by surgery
Number of subjects: 743
Study 39482336 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Recombinant COVID-19 Vaccine (Ad5-nCoV-IH)
Number of subjects: 540
Study 39482336 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular tozinameran (BNT-IM)
Number of subjects: 540
Study 39482393 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill training
Number of subjects: 30
Study 39482393 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional treadmill training
Number of subjects: 30
Study 39482393 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 39482484 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interleukin 2 (Ld-IL2) therapy along with standard treatment for 12 weeks
Number of subjects: 60
Study 39482484 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 60
Study 39482707 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated model using cfDNA methylation patterns, protein profiling, and CT imaging features
Number of subjects: 419
Study 39482707 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated model
Number of subjects: 419
Study 39482707 — intervention group
Group type: COMPARATOR
Intervention: Individual methylation model
Number of subjects: 419
Study 39482707 — intervention group
Group type: COMPARATOR
Intervention: Individual protein model
Number of subjects: 419
Study 39482707 — intervention group
Group type: COMPARATOR
Intervention: Individual imaging model
Number of subjects: 419
Study 39482712 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus peel extract (400 mg containing 3.0 mg of naringenin and 0.1 mg of auraptene)
Number of subjects: 80
Study 39482712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 39482712 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus peel extract
Number of subjects: 80
Study 39482774 — intervention group
Group type: EXPERIMENTAL
Intervention: NSS HVA (defined as low carotid-femoral pulse wave velocity)
Number of subjects: 3234
Study 39482774 — intervention group
Group type: EXPERIMENTAL
Intervention: NSS HVA
Number of subjects: 3234
Study 39482774 — intervention group
Group type: COMPARATOR
Intervention: Non-NSS HVA (control group)
Number of subjects: 3234
Study 39482930 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab (240 mg) + bevacizumab (7.5 mg/kg) + platinum-based chemotherapy (once every three weeks for six cycles, followed by maintenance therapy for 12 months)
Number of subjects: 24
Study 39483049 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective closed kinetic chain exercises (NSKCE)
Number of subjects: 80
Study 39483049 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective closed kinetic chain exercises (SCKCE)
Number of subjects: 80
Study 39483049 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 80
Study 39483442 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Metacognitive Therapy (MCT) added to usual CR
Number of subjects: 0
Study 39483442 — intervention group
Group type: COMPARATOR
Intervention: Usual Cardiac Rehabilitation (CR)
Number of subjects: 0
Study 39483517 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred local treatment of the primary tumour (experimental arm) consisting of (partial) cytoreductive nephrectomy, any form of ablative local therapy, or magnetic resonance imaging guided ablative stereotactic radiotherapy, performed within 6 months and 1.5 years after the start of systemic treatment.
Number of subjects: 700
Study 39483517 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) (control arm).
Number of subjects: 700
Study 39483518 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiomics and immunohistopathological analyses on biosamples (blood, urine, and BC tissue) collected from patients at diagnosis.
Number of subjects: 300
Study 39483518 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiomics analyses to identify multibiomarker panels for better stratification of NMIBC.
Number of subjects: 300
Study 39483518 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of patient subgroup response to bacillus Calmette-Guérin treatment.
Number of subjects: 300
Study 39483619 — intervention group
Group type: EXPERIMENTAL
Intervention: AFQ056 (mavoglurant)
Number of subjects: 0
Study 39483619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39483877 — intervention group
Group type: EXPERIMENTAL
Intervention: TARANG intervention
Number of subjects: 42
Study 39483896 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted implementation support (training, championship, practice facilitation, audit and feedback)
Number of subjects: 20
Study 39483915 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-driven OUD screener embedded in the electronic health record (EHR)
Number of subjects: 0
Study 39483915 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 39484118 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use at baseline
Number of subjects: 784
Study 39484118 — intervention group
Group type: COMPARATOR
Intervention: Mild depression
Number of subjects: 784
Study 39484131 — intervention group
Group type: EXPERIMENTAL
Intervention: SII Q1: <1707.31 (×10)
Number of subjects: 3808
Study 39484131 — intervention group
Group type: COMPARATOR
Intervention: SII Q2: ≥1707.31 (×10)
Number of subjects: 3808
Study 39484239 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightmode decoder for brain-computer interface (BCI)
Number of subjects: 0
Study 39484239 — intervention group
Group type: COMPARATOR
Intervention: Daytime decoders
Number of subjects: 0
Study 39484239 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightmode decoder
Number of subjects: 0
Study 39484240 — intervention group
Group type: EXPERIMENTAL
Intervention: aTIV (adjuvanted trivalent inactivated flu vaccine)
Number of subjects: 387
Study 39484240 — intervention group
Group type: COMPARATOR
Intervention: HD-IIV3 (high-dose flu vaccine)
Number of subjects: 387
Study 39484244 — intervention group
Group type: EXPERIMENTAL
Intervention: WSH or nutrition interventions
Number of subjects: 1409
Study 39484244 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1409
Study 39484284 — intervention group
Group type: EXPERIMENTAL
Intervention: CH505TF + GLA-SE
Number of subjects: 38
Study 39484284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 39485113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid nuclear and fluoroscopy C-arm scanner
Number of subjects: 12
Study 39485256 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized neoantigen-encoding mRNA vaccines
Number of subjects: 16
Study 39485256 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized vaccines plus pembrolizumab
Number of subjects: 16
Study 39485259 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of the intervention (specific intervention not mentioned)
Number of subjects: 0
Study 39485259 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 39485352 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga now (virtual yoga classes)
Number of subjects: 140
Study 39485352 — intervention group
Group type: COMPARATOR
Intervention: Yoga later (wait-list control)
Number of subjects: 140
Study 39485351 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal RBC transfusion strategy (Hb <10 g/dL)
Number of subjects: 3144
Study 39485351 — intervention group
Group type: COMPARATOR
Intervention: Restrictive RBC transfusion strategy (Hb <7-8 g/dL)
Number of subjects: 3144
Study 39485351 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute anemia
Number of subjects: 3144
Study 39485351 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic anemia
Number of subjects: 3144
Study 39485534 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-wise compartmental analysis of dynamic imaging
Number of subjects: 11
Study 39485534 — intervention group
Group type: EXPERIMENTAL
Intervention: Delaying the starting point of the compartmental analysis
Number of subjects: 11
Study 39485585 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-BfB training (live format)
Number of subjects: 73
Study 39485585 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-BfB training (digital format)
Number of subjects: 73
Study 39485585 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 73
Study 39485702 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine pH-Ammonium Acid/Base Score
Number of subjects: 0
Study 39485760 — intervention group
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri ATCC PTA 6475 (single strain)
Number of subjects: 65
Study 39485760 — intervention group
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri DSM 17938 (dual strain)
Number of subjects: 65
Study 39485760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 39485833 — intervention group
Group type: EXPERIMENTAL
Intervention: Micra AV leadless pacemaker
Number of subjects: 116110
Study 39485833 — intervention group
Group type: COMPARATOR
Intervention: DC-TV pacemaker
Number of subjects: 116110
Study 39485887 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior mesenteric artery approach
Number of subjects: 101
Study 39485887 — intervention group
Group type: COMPARATOR
Intervention: No-touch approach
Number of subjects: 101
Study 39485887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cluster mobilization
Number of subjects: 101
Study 39485887 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein resection
Number of subjects: 101
Study 39486004 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed permanent ceramic-filled resin (PCR) restorations
Number of subjects: 30
Study 39486022 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-CHESS app
Number of subjects: 33
Study 39486022 — intervention group
Group type: COMPARATOR
Intervention: A-CHESS app
Number of subjects: 33
Study 39486046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan 270 mg/day
Number of subjects: 24
Study 39486046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan 360 mg/day
Number of subjects: 24
Study 39486046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (both dosages)
Number of subjects: 24
Study 39486089 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ibuzatrelvir
Number of subjects: 240
Study 39486089 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ibuzatrelvir
Number of subjects: 240
Study 39486089 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuzatrelvir
Number of subjects: 240
Study 39486089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 39486163 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI every 2 weeks after failure of a prior oxaliplatin-based regimen
Number of subjects: 137
Study 39486163 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 137
Study 39486165 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 596
Study 39486209 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education program (PNE) - 10 sessions over 5 weeks, each lasting 40-45 minutes.
Number of subjects: 62
Study 39486209 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment supplemented with PNE
Number of subjects: 62
Study 39486209 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacological treatment
Number of subjects: 62
Study 39486424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 216
Study 39486424 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (carboplatin plus pemetrexed)
Number of subjects: 216
Study 39486432 — intervention group
Group type: EXPERIMENTAL
Intervention: Valemetostat 150 mg per day
Number of subjects: 90
Study 39486432 — intervention group
Group type: EXPERIMENTAL
Intervention: Valemetostat 200 mg per day
Number of subjects: 90
Study 39486432 — intervention group
Group type: EXPERIMENTAL
Intervention: Valemetostat 250 mg per day
Number of subjects: 90
Study 39486432 — intervention group
Group type: EXPERIMENTAL
Intervention: Valemetostat 300 mg per day
Number of subjects: 90
Study 39486433 — intervention group
Group type: EXPERIMENTAL
Intervention: Valemetostat at 200 mg per day in continuous 28-day cycles until disease progression or unacceptable toxicity
Number of subjects: 155
Study 39486433 — intervention group
Group type: EXPERIMENTAL
Intervention: Valemetostat
Number of subjects: 155
Study 39486439 — intervention group
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri DSM 17938 supplementation for six weeks
Number of subjects: 89
Study 39486439 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 89
Study 39486439 — intervention group
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri DSM 17938 supplementation
Number of subjects: 89
Study 39486645 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT (definitive local treatment to all sites of disease, plus SOC systemic therapy)
Number of subjects: 43
Study 39486645 — intervention group
Group type: COMPARATOR
Intervention: SOC systemic therapy-only
Number of subjects: 43
Study 39486645 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT
Number of subjects: 43
Study 39486684 — intervention group
Group type: EXPERIMENTAL
Intervention: BHIP prenatal diet-and-exercise intervention
Number of subjects: 0
Study 39486684 — intervention group
Group type: COMPARATOR
Intervention: Usual pregnancy care (UPC)
Number of subjects: 0